CoChat

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial

Open access
DeAngelo, Daniel J., Radia, Deepti H., George, Tracy I., Robinson, William A., Quiery, Albert T., Drummond, Mark W., Bose, Prithviraj, Hexner, Elizabeth O., Winton, Elliott F., Horny, Hans-Peter, Tugnait, Meera, Schmidt-Kittler, Oleg, Evans, Erica K., Lin, Hui-Min, Mar, Brenton G., Verstovsek, Srdan, Deininger, Michael W., Gotlib, Jason · 2021 · Nature Medicine
Cited by 153

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Advanced systemic mastocytosis (AdvSM) is a rare hematologic neoplasm driven by the KIT D816V mutation and associated with poor survival. This phase 1 study (NCT02561988) evaluated avapritinib (BLU-285), a selective KIT D816V inhibitor, in patients with AdvSM. The primary endpoints were the maximum tolerated dose, recommended phase 2 dose and safety of avapritinib. Secondary endpoints included overall response rate and changes in measures of mast cell burden. Avapritinib was evaluated at doses of 30–400 mg once daily in 86 patients, 69 with centrally confirmed AdvSM. Maximum tolerated dose was not reached, and 200 mg and 300 mg daily were studied in dose-expansion cohorts. The most frequent adverse events observed were periorbital edema (69%), anemia (55%), diarrhea (45%), thrombocytopenia (44%) and nausea (44%). Intracranial bleeding occurred in 13% overall, but in only 1% of patients without severe thrombocytopenia (platelets <50 × 10 9/l). In 53 response-evaluable patients, the overall response rate was 75%. The complete remission rate was 36%. Avapritinib elicited ≥50% reductions in marrow mast cells and serum tryptase in 92% and 99% of patients, respectively. Avapritinib induced deep and durable responses, including molecular remission of KIT D816V in patients with AdvSM, and was well tolerated at the recommended phase 2 dose of 200 mg daily.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01538-9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 153

Metadata

Authors
DeAngelo, D. J., Radia, D. H., George, T. I., Robinson, W. A., Quiery, A. T., Drummond, M. W., Bose, P., Hexner, E. O., Winton, E. F., Horny, H.-P., Tugnait, M., Schmidt-Kittler, O., Evans, E. K., Lin, H.-M., Mar, B. G., Verstovsek, S., Deininger, M. W., & Gotlib, J.
Venue
Nature Medicine
Published
2021-12
Volume
27
Issue
12
Pages
2183-2191
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4200317891
Cited by
153
References
2
FWCI
7.66
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. https://app.cochat.ai/papers/10.1038/s41591-021-01538-9
The paper
DeAngelo, D. J., Radia, D. H., George, T. I., Robinson, W. A., Quiery, A. T., Drummond, M. W., Bose, P., Hexner, E. O., Winton, E. F., Horny, H.-P., Tugnait, M., Schmidt-Kittler, O., Evans, E. K., Lin, H.-M., Mar, B. G., Verstovsek, S., Deininger, M. W., & Gotlib, J. (2021). Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. Nature Medicine. https://doi.org/10.1038/s41591-021-01538-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.